Adlai NortyeANL -1.57% Pretax Margin % is -343.86% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 945 Biotechnology companies, Adlai Nortye ranks worse than 74.81% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Adlai Nortye's Pre-Tax Income for the
six
months ended in Dec. 2025 was $-17.19 Mil. Adlai Nortye's Revenue for the
six
months ended in Dec. 2025 was $5.00 Mil. Therefore, Adlai Nortye's pretax margin for the quarter that ended in Dec. 2025 was -343.86%.
The historical rank and industry rank for Adlai Nortye's Pretax Margin % or its related term are showing as below:
ANL'
s Pretax Margin % Range Over the Past 10 Years
Min: -710.56 Med: -417.26 Max: -123.95
Current: -710.56
ANL's Pretax Margin % is ranked worse than 74.81% of 945
companies
in the Biotechnology industry
Industry Median: -90.63
vs ANL: -710.56
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Adlai Nortye Pretax Margin % Related Terms
Adlai Nortye Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANL vs PHAT, AURA, RLMD: Pretax Margin % Comparison
For the Biotechnology subindustry, Adlai Nortye's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (ANL) has a Pretax Margin % of -343.86% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #707 out of 945 companies in the Biotechnology industry, placing it in the top 74.8%.
Is Adlai Nortye's Pretax Margin % too high?
Adlai Nortye's current Pretax Margin % is -343.86%. Based on the distribution chart, Adlai Nortye ranks #707 out of 945 companies in the Biotechnology industry, which is below the industry midpoint.
How does Adlai Nortye's Pretax Margin % compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #707 out of 945 companies for Pretax Margin %. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Pretax Margin % is -343.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Pretax Margin % of -343.86%. The current Pretax Margin % is -343.86%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Pretax Margin % is -343.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 